Pregabalin Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0034/G 
This was an application for a group of variations. 
09/01/2023 
SmPC and PL 
To update Section 4.4 and 4.8 of the SmPC to reflect new 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
data on suicidal ideation. PL has been updated accordingly. 
To update sections 4.4 and 4.8 of the SmPC to implement 
the wording related to the cases of abuse and dependence. 
PL has been updated accordingly. 
product - Implementation of change(s) for which NO 
To update SmPC sections 4.4 and 4.8 with a warning 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
new additional data is required to be submitted by 
regarding severe cutaneous adverse reactions. The PL was 
updated accordingly. 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0032/G 
This was an application for a group of variations. 
29/07/2022 
n/a 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
down to 10-fold 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
IA/0033/G 
This was an application for a group of variations. 
08/07/2022 
n/a 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
B.II.e.3.a - Change in test procedure for the 
Page 3/12 
 
 
 
 
 
 
 
 
 
immediate packaging of the finished product - Minor 
changes to an approved test procedure 
IB/0029 
C.I.2.a - Change in the SPC, Labelling or PL of a 
20/04/2022 
13/06/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0031 
B.II.b.4.a - Change in the batch size (including batch 
29/03/2022 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IA/0030 
B.II.b.4.a - Change in the batch size (including batch 
29/03/2022 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IAIN/0028 
To update sections 4.4 and 4.8 of the SmPC and 
29/03/2022 
13/06/2022 
SmPC and PL 
sections 2 and 4 of the PL to implement the signal 
recommendations on ‘Pregabalin – Toxic epidermal 
necrolysis’ (EPITT no 19723) adopted at the 10-13 
January 2022 PRAC meeting. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
IA/0027/G 
This was an application for a group of variations. 
02/02/2022 
n/a 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
Page 4/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
dossier) - Replacement or addition of a supplier 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
IA/0026 
A.7 - Administrative change - Deletion of 
17/01/2022 
13/06/2022 
Annex II and 
manufacturing sites 
PL 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/01/2022 
13/06/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0024 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/11/2021 
13/06/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0021 
B.II.b.3.z - Change in the manufacturing process of 
08/02/2021 
n/a 
the finished or intermediate product - Other variation 
IB/0022/G 
This was an application for a group of variations. 
19/01/2021 
13/06/2022 
SmPC, Annex 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
II, Labelling 
and PL 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0023 
B.II.b.3.z - Change in the manufacturing process of 
08/01/2021 
n/a 
the finished or intermediate product - Other variation 
IA/0020 
B.III.1.a.2 - Submission of a new/updated or 
18/11/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0019 
B.II.b.4.a - Change in the batch size (including batch 
19/10/2020 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IAIN/0018 
B.II.b.1.a - Replacement or addition of a 
14/07/2020 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
R/0015 
Renewal of the marketing authorisation. 
30/04/2020 
03/07/2020 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Pregabalin Accord in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
Page 6/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0017/G 
This was an application for a group of variations. 
20/01/2020 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0016/G 
This was an application for a group of variations. 
12/12/2019 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0014/G 
This was an application for a group of variations. 
10/12/2019 
08/04/2020 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.III.1.a.1 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Page 8/12 
 
 
 
 
 
 
 
 
 
IA/0013 
B.II.d.2.a - Change in test procedure for the finished 
14/08/2019 
n/a 
product - Minor changes to an approved test 
procedure 
IA/0012 
B.II.b.2.a - Change to importer, batch release 
08/03/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0011 
B.II.b.2.c.1 - Change to importer, batch release 
08/03/2019 
08/04/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0010 
Transfer of Marketing Authorisation 
01/02/2019 
05/03/2019 
SmPC, 
Labelling and 
PL 
IAIN/0009/G 
This was an application for a group of variations. 
14/12/2018 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 9/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0008 
B.III.1.a.3 - Submission of a new/updated or 
05/03/2018 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IB/0007 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/02/2018 
23/01/2019 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/11/2017 
23/01/2019 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0004/G 
This was an application for a group of variations. 
31/05/2017 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.III.2.a.1 - Change of specification(s) of a former 
Page 10/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
IB/0005 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/05/2017 
26/06/2017 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/04/2017 
26/06/2017 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0002 
B.II.e.5.a.1 - Change in pack size of the finished 
21/12/2015 
12/12/2016 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
IA/0001/G 
This was an application for a group of variations. 
09/09/2015 
n/a 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
Page 11/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 12/12 
 
 
 
 
 
 
 
